[go: up one dir, main page]

DK3986920T3 - Tnfr2-agonister med forbedret stabilitet - Google Patents

Tnfr2-agonister med forbedret stabilitet Download PDF

Info

Publication number
DK3986920T3
DK3986920T3 DK20733658.7T DK20733658T DK3986920T3 DK 3986920 T3 DK3986920 T3 DK 3986920T3 DK 20733658 T DK20733658 T DK 20733658T DK 3986920 T3 DK3986920 T3 DK 3986920T3
Authority
DK
Denmark
Prior art keywords
improved stability
tnfr2 agonists
tnfr2
agonists
stability
Prior art date
Application number
DK20733658.7T
Other languages
English (en)
Inventor
Roman Fischer
Martin Siegemund
Klaus Pfizenmaier
Roland Kontermann
Original Assignee
Univ Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart filed Critical Univ Stuttgart
Application granted granted Critical
Publication of DK3986920T3 publication Critical patent/DK3986920T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK20733658.7T 2019-06-24 2020-06-24 Tnfr2-agonister med forbedret stabilitet DK3986920T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19182102 2019-06-24
PCT/EP2020/067656 WO2020260368A1 (en) 2019-06-24 2020-06-24 Tnfr2 agonists with improved stability

Publications (1)

Publication Number Publication Date
DK3986920T3 true DK3986920T3 (da) 2025-06-10

Family

ID=67107343

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20733658.7T DK3986920T3 (da) 2019-06-24 2020-06-24 Tnfr2-agonister med forbedret stabilitet

Country Status (8)

Country Link
US (2) US20220267410A1 (da)
EP (2) EP3986920B1 (da)
JP (1) JP7616671B2 (da)
AU (1) AU2020301529A1 (da)
CA (1) CA3140664A1 (da)
DK (1) DK3986920T3 (da)
ES (1) ES3031566T3 (da)
WO (1) WO2020260368A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11530247B2 (en) 2017-06-06 2022-12-20 Relinia, Inc. Single-chain TNF receptor 2 agonist fusion proteins
DK3986920T3 (da) * 2019-06-24 2025-06-10 Univ Stuttgart Tnfr2-agonister med forbedret stabilitet
JPWO2023095913A1 (da) * 2021-11-29 2023-06-01
TW202530263A (zh) 2023-09-28 2025-08-01 德商雷薩諾有限責任公司 促效劑多肽
TW202519543A (zh) 2023-09-29 2025-05-16 美商崔克斯生物公司 TNF-α變體融合分子

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944399A (ja) 1982-09-07 1984-03-12 Takeda Chem Ind Ltd 新規ｄｎａ
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
CA2090105A1 (en) 1990-08-29 1992-03-01 Jean-Paul Soulillou Protein polyligands joined to a stable protein core
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
WO2000047740A2 (en) 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
CA2409746C (en) 2000-05-18 2014-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2002088317A2 (en) 2001-05-01 2002-11-07 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
US7488804B2 (en) 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
DE102005036542A1 (de) 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
AU2007240491A1 (en) 2006-04-13 2007-11-01 Zymogenetics, Inc. Tetramerizing polypeptides and methods of use
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
CN107011445B (zh) 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
US8383774B2 (en) 2007-07-10 2013-02-26 Apogenix Gmbh Collectin fusion proteins comprising TNF or trail
ES2571879T3 (es) 2008-07-21 2016-05-27 Apogenix Ag Moléculas de una sola cadena de TNFSF
JP2012507299A (ja) 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｇｈｔ標的分子およびその使用
KR20110097913A (ko) 2008-12-04 2011-08-31 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
EP3798237A1 (en) 2010-03-05 2021-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
JPWO2012020842A1 (ja) 2010-08-13 2013-10-28 独立行政法人理化学研究所 腫瘍ワクチン効果を有する複合体及びその用途
JP2014523900A (ja) 2011-06-28 2014-09-18 インヒブルクス リミティド ライアビリティ カンパニー セルピン融合ポリペプチド及びその使用方法
JP5956580B2 (ja) 2011-09-16 2016-07-27 北京沙▲東▼生物技▲術▼有限公司Ｂｅｉｊｉｎｇ Ｓｕｎｂｉｏ Ｂｉｏｔｅｃｈ Ｃｏ．， Ｌｔｄ． Ｔｒａｉｌ／ａｐｏ２ｌの円順列変異形を含む融合タンパク質、コーディング遺伝子およびそれらの使用
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
US11142558B2 (en) 2017-04-06 2021-10-12 Universität Stuttgart Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
US11530247B2 (en) * 2017-06-06 2022-12-20 Relinia, Inc. Single-chain TNF receptor 2 agonist fusion proteins
DK3986920T3 (da) * 2019-06-24 2025-06-10 Univ Stuttgart Tnfr2-agonister med forbedret stabilitet

Also Published As

Publication number Publication date
JP7616671B2 (ja) 2025-01-17
AU2020301529A1 (en) 2022-01-06
ES3031566T3 (en) 2025-07-09
EP4582442A2 (en) 2025-07-09
EP3986920A1 (en) 2022-04-27
EP4582442A3 (en) 2025-10-29
EP3986920B1 (en) 2025-04-16
US20240228581A1 (en) 2024-07-11
CA3140664A1 (en) 2020-12-30
US12173046B2 (en) 2024-12-24
WO2020260368A1 (en) 2020-12-30
JP2022537831A (ja) 2022-08-30
US20220267410A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
IL280913A (en) Novel methods
HUE062096T2 (hu) Piridazinonok PARP7-inhibitorokként
DK3986920T3 (da) Tnfr2-agonister med forbedret stabilitet
EP3750579A4 (en) INJECTOR
EP3828822C0 (en) CIVIL ENGINEERING
EP3747921A4 (en) COMPOSITION OF SEQUENCED COPOLYMER
DK3619521T3 (da) Højgennemløbssekventering med halvlederbaseret detektering
EP3826702A4 (en) INJECTOR
DK3591122T3 (da) Hurtigskifter
EP3871694A4 (en) COMPOSITION
EP4028710C0 (de) Schusswaffe
EP3853274A4 (en) TWO-COMPOSITION BLOCK COPOLYMERS
DK3840596T3 (da) Sammensætning
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP4079787A4 (en) CURABLE COMPOSITION
EP3981256A4 (en) COMPOSITION
EP3927402A4 (en) Injector
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
EP4026694A4 (en) FLUORINE-CONTAINING COPOLYMER
EP3941942A4 (en) Composition
EP3931385A4 (en) Nanofiber surfaces
DK3660065T3 (da) Midler med forbedret virksomhed som brabdhæmmende midler
EP3801538A4 (en) TLR7 AGONISTS
EP3957391C0 (en) AGITATOR